Skip to main content

Advertisement

SpringerLink
Log in

Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To determine in the same blood sample the concentrations of cyclosporin A (CsA) and the degree of CsA-induced lymphocyte inhibition; to establish a relationship between these parameters; and to investigate the factor(s) influencing such a putative relationship.

Methods

Ten patients with a diagnosis of Crohn’s disease (n=7) or ulcerative colitis (n=3) were enrolled in the study. The patients, who had never been immunosuppressed, were treated with microemulsion CsA twice daily by the oral route; at steady-state, blood samples were collected 0, 0.5, 1, 2, 3, 5, 7 and 12 h after the morning dose. CsA blood levels were measured by means of radioimmunoassay. The percentages of lymphocytes during the S-phase were assessed by flow-cytometry on the same blood specimens, only for samples collected at 0 h and 2 h.

Results

An inverse relationship emerged between CsA blood concentrations and the percentage of lymphocytes during the S-phase: the latter was maximal before the beginning of treatment and minimal in association with peak CsA levels. Furthermore, a highly significant correlation was found between trough CsA levels and the age of the patient, since the percentage of inhibited lymphocytes increases with age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Batiuk TD, Kung L, Halloran PF (1997) Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 100:1894–1901

    CAS  PubMed  Google Scholar 

  2. Halloran PF, Kung L, Noujaim J (1998) Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 30:2167–2170

    Google Scholar 

  3. Latteri M, Angeloni G, Gentiloni Silveri N, Manna R, Gasbarrini G, Navarra P (2001) Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. Clin Pharmacokinet 40:473–483

    Google Scholar 

  4. Mitsuyama K, Suzuki A, Tomiyasu N, Takaki K, Toyonaga A, Sata M (2001) Transcription factor-targeted therapies in inflammatory bowel disease. Digestion 63[Suppl 1]:68–72

  5. Bussa S, Rumi C, Leone G, Bizzi B (1993) Evaluation of a new whole blood cytometric lymphocyte transformation test for immunological screenings. J Clin Lab Immunol 40:39–46

    CAS  PubMed  Google Scholar 

  6. d’Uscio CH, Aweeka FT, Prueksaritanont T, Tomlanovich SJ, Gupta SK, Lantz MV, Gambertoglio JG, Garovoy MR, Benet LZ (1995) Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation. J Clin Pharmacol 10:967–973

    Google Scholar 

  7. Fukuda T, Asakawa J, Motojima S, Makino S (1995) Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann Allergy Asthma Immunol 75:65–72

    CAS  PubMed  Google Scholar 

  8. Mora JR, Bono MR, Rosemblatt M, Rodriguez S, Morales J, Buckel E, Fierro A (2001) CD4 and CD8 cytokine-producing T cells are transiently reduced following cyclosporine intake: maximal inhibition occurs at 2 hours coincidental with drug C(max). Transplant Proc 33:3310–3312

    Article  CAS  PubMed  Google Scholar 

  9. Briggs WA, Gao ZH, Gimenez LF, Scheel PJ Jr, Choi MJ, Burdick JF (1996) Lymphocyte responsiveness to glucocorticoids, cyclosporine, or both. J Clin Pharmacol 36:707–714

    CAS  PubMed  Google Scholar 

  10. Hirano T, Oka K, Takeuchi H, Kozaki K, Matsuno N, Nagao T, Kozaki M, Ichikawa M, Yoshida M, Umezawa Y, Hirata M, Oh-i T, Koga M (1997) Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy. Clin Pharmacol Ther 62:652–664

    CAS  PubMed  Google Scholar 

  11. Briggs WA, Eustace J, Mathew S, Gimenez LF, Choi M, Scheel PJ Jr, Burdick J (1998) Pentoxifylline potentiates in vitro lymphocyte suppression by glucocorticoids and immunosuppressive drugs. J Clin Pharmacol 38:561–566

    CAS  PubMed  Google Scholar 

  12. Briggs WA, Eustace J, Gimenez LF, Choi MJ, Scheel PJ Jr, Burdick JF (1999) Lymphocyte suppression by glucocorticoids with cyclosporine, tacrolimus, pentoxifylline, and mycophenolic acid. J Clin Pharmacol 39:125–130

    Article  CAS  PubMed  Google Scholar 

  13. McCormack G, O’Donoghue D, Baird A (2001) In-vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in-vivo therapeutic response in ulcerative colitis. Aliment Pharmacol Ther 15:665–668

    Article  CAS  PubMed  Google Scholar 

  14. Stio M, Treves C, Celli A, Tarantino O, d’Albasio G, Bonanomi AG (2002) Synergistic inhibitory effect of cyclosporin A and vitamin D derivatives on T-lymphocyte proliferation in active ulcerative colitis. Am J Gastroenterol 97:679–689

    Article  CAS  PubMed  Google Scholar 

  15. Woodside KJ, Hu M, Meng T, Hunter GC, Sower LE, Daller JA (2003) Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes. Transplantation 75:1631–1635

    Article  CAS  PubMed  Google Scholar 

  16. Morales JM, Campistol JM, Andres A, Herrero JC (2000) Immunosuppression in older renal transplant patients. Drugs Aging 16:279–287

    Google Scholar 

  17. Bradley BA (2002) Rejection and recipient age. Transpl Immunol 10:125–132

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ‘Centro di Ricerca e Formazione ad alta Tecnologia nelle Scienze Biomediche’, Campobasso, Italy

    Giulia Angeloni

  2. Division of Internal Medicine, Ospedale Civile, Cuorgné, Turin, Italy

    Miriam Latteri

  3. Institute of Internal Medicine and Geriatric, Catholic University Medical School, Rome, Italy

    Raffaele Manna & Giovanni Gasbarrini

  4. Institute of Haematology, Catholic University Medical School, Rome, Italy

    Carlo Rumi

  5. Institute of Pharmacology, Catholic University Medical School, Largo Francesco Vito 1-00168, Rome, Italy

    Pierluigi Navarra

Authors
  1. Giulia Angeloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miriam Latteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaele Manna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo Rumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Gasbarrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pierluigi Navarra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierluigi Navarra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Angeloni, G., Latteri, M., Manna, R. et al. Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients. Eur J Clin Pharmacol 60, 161–164 (2004). https://doi.org/10.1007/s00228-004-0743-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0743-2

Keywords

Search

Navigation